Abstract
MEDI4736 is an engineered human IgG1 that blocks PD-L1 binding to PD-1 and allows T-cells to recognize and kill tumor. MEDI4736 has single-agent activity and potential for further increased activity in combination. A comprehensive development programme is underway in NSCLC, as monotherapy and in combination.
Cite
CITATION STYLE
Brahmer, J., Balmanoukian, A., Goldberg, S., Ou, S.-H., Blake-Haskins, A., Karakunnel, J., … Antonia, S. (2014). Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC). Journal for ImmunoTherapy of Cancer, 2(S3). https://doi.org/10.1186/2051-1426-2-s3-p179
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
